OurStoriesRx (@ourstoriesrx) 's Twitter Profile
OurStoriesRx

@ourstoriesrx

Our Stories Rx is a storytelling project that brings together patient advocates, community clinicians and independent pharmacists being harmed by PBMs.

ID: 1436168167198322704

linkhttp://OurstoriesRx.com calendar_today10-09-2021 03:22:44

348 Tweet

173 Followers

163 Following

OurStoriesRx (@ourstoriesrx) 's Twitter Profile Photo

Iowa is leading by example when it comes to #PBM reform! Lawmakers are considering legislation to require PBMs reimburse pharmacies adequately for dispensing prescription drugs: kcrg.com/2025/01/31/sta…

OurStoriesRx (@ourstoriesrx) 's Twitter Profile Photo

#ICYMI: Earlier this year, two #PBMs were caught colluding to fix prices for HIV/AIDS treatments and forced to pay $10 million in damages. Accountability NOW: startribune.com/eagans-prime-t…

OurStoriesRx (@ourstoriesrx) 's Twitter Profile Photo

Cheering on our local #pharmacist community in Kansas as they continue to push for #PBM reform! kcur.org/health/2025-02…

OurStoriesRx (@ourstoriesrx) 's Twitter Profile Photo

Good news from Indiana: An opportunity for lawmakers at the state level to get a "seat at the table" when defining the role of #PBMs! wbaa.org/local-news/202…

OurStoriesRx (@ourstoriesrx) 's Twitter Profile Photo

"We found that pharmacies will face payment delays of at least a week beyond current terms; they will lose $11,000 per week in cash flow; and they could lose as much as $43,000 annually." drugtopics.com/view/alarm-bel…

OurStoriesRx (@ourstoriesrx) 's Twitter Profile Photo

“It's about rebate transparency, right? That's a big deal, right? All we want #PBMs to do is to be transparent:" contemporaryclinic.com/view/pbm-refor…

OurStoriesRx (@ourstoriesrx) 's Twitter Profile Photo

"A survey found that 72 percent of Medicare Part D formularies placed at least one brand-name drug in a tier with lower cost-sharing than its generic equivalent." This is how #PBMs profit: dcjournal.com/why-your-pharm…

OurStoriesRx (@ourstoriesrx) 's Twitter Profile Photo

"Middlemen drive up drug prices by roughly 50 percent. PBMs and big insurance companies take 25 percent. Along with massive hospitals, they abuse a little-known government program called 340B to take another $66 billion or 10 percent." breitbart.com/politics/2025/…

OurStoriesRx (@ourstoriesrx) 's Twitter Profile Photo

Together, our stories help piece together a broken health care landscape. Our Stories Rx is a storytelling project that elevates voices from across the health care system, bringing accountability to an otherwise opaque industry. Tell you story: ourstoriesrx.com

OurStoriesRx (@ourstoriesrx) 's Twitter Profile Photo

Thank you to the Chronic Disease Coalition for the thorough policy update on #PBM Reform and other federal priorities: chronicdiseasecoalition.org/news/april-202…

OurStoriesRx (@ourstoriesrx) 's Twitter Profile Photo

"The report concluded that #PBMs have continuously profited by overcharging patients for medications and influencing where the patient can obtain their prescriptions." pharmacytimes.com/view/pbm-refor…

OurStoriesRx (@ourstoriesrx) 's Twitter Profile Photo

Together, our stories help piece together a broken health care landscape. Our Stories Rx is a storytelling project that elevates voices from across the health care system, bringing accountability to an otherwise opaque industry: ourstoriesrx.com

OurStoriesRx (@ourstoriesrx) 's Twitter Profile Photo

“It makes sure that dollars in the system actually benefit the patient, bring down their drug costs and premiums, and ensure pharmacies are paid what it costs to stock those drugs — ultimately giving patients more choice in care.” cbs2iowa.com/news/local/gop…

OurStoriesRx (@ourstoriesrx) 's Twitter Profile Photo

#340B and #PBM reform are tethered: Both close loopholes that pass savings on to #patients. Read more about efforts to make change in Kentucky: linknky.com/opinion/2025/0…

OurStoriesRx (@ourstoriesrx) 's Twitter Profile Photo

"I think there's 3 main buckets of #PBM reform. One is legislation, one is litigation, and another is market-based solutions." Hear more from Antonio Ciaccia about opportunities for reform: drugtopics.com/view/the-3-typ…